🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — looking for input Page 5

SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — looking for input

Admin Sat, Jul 12, 2025 at 7:09 AM 40 replies 1,896 viewsPage 5 of 8
nick_SD_fit
Member
278
1,234
Sep 2024
San Diego, CA
Aug 14, 2025 at 4:58 PM#21
LindaRN_retired said:
Start from the measurement rather than the conclusion.

Adding the part of the answer the thread has not reached. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

2 0SkepticalSean, Dr.CardioMD
Reply Quote Save Share Report
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Aug 28, 2025 at 7:54 AM#22

Adding the numbers, since they settle part of this. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

3 1Dr.ObesityLA, NurseKim_ATL, paul_denver
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Sep 10, 2025 at 10:42 PM#23

A narrower follow-up, since the general answer is now clear:

How much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical?

4 2ingrid_STO, pete_nash, hank_denver and 1 other
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Sep 24, 2025 at 1:22 PM#24
josh_phd_bmore said:
If you are going to change something, change one thing and give it long enough to express itself.

This is where I part company with the consensus forming above. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.

Last edited: Sep 24, 2025 at 7:22 PM
5 3stefan_berlin, Dr.EM_Chicago, pete_RVA and 2 others
Reply Quote Save Share Report
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
Oct 8, 2025 at 3:54 AM#25
josh_phd_bmore said:
If you are going to change something, change one thing and give it long enough to express itself.

Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

6 4pam_columbus, nick_SD_fit, ben_calgary and 3 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register